LIFECORE BIOMEDICAL INC DE
For the period ended Aug 25, 2024. Filed Oct 4, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Aug 25, 2024 · Filed Oct 4, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Revenue
- Revenue
The Company disaggregates its revenue based on how it markets its products and services and reviews results of operations. The following table disaggregates revenues by major product lines and services:
| Three Months Ended | ||
|---|---|---|
| August 25, 2024 | August 27, 2023 | |
| CDMO | $20,180 | $21,539 |
| Fermentation | 4,525 | 2,983 |
| Total | $24,705 | $24,522 |
The following table disaggregates revenues by the timing of revenue recognition:
| Three Months Ended | ||
|---|---|---|
| August 25, 2024 | August 27, 2023 | |
| CDMO - Developmental Services revenue recognized over time | $5,876 | $6,381 |
| Revenues recognized at a point in time | 18,829 | 18,141 |
| Total | $24,705 | $24,522 |
During the three months ended August 25, 2024, the Company had revenues concentrations of 10% or greater from two customers, accounting for 32% and 24%. During the three months ended August 27, 2023, the Company had revenues concentrations of 10% or greater from three customers, accounting for 31%,21%, and 15%.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.